Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2021-05-20 Interim / Quarterly Rep…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
CELON_RAPORT_Q1_2021.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPORT KWARTALNY ZA I KWARTAŁ 2021' (Quarterly Report for Q1 2021) for Celon Pharma S.A. It contains detailed information about the company, management, board composition, share capital, and accounting policies. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-20 Polish
Zmiana terminu publikacji raportu okresowego za I kwartał 2021 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text is very short (340 characters) and explicitly states that the company's management (Zarząd) is informing about a CHANGE IN THE DATE ('zmianie terminu') for the publication of the periodic report for Q1 2021. It announces the new publication date (May 20, 2021) and compares it to the original date. This is not the report itself (which would be an IR), but an announcement about the timing of a report's release. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2021-05-17 Polish
2021-05-10_Uchwala_Zarzadu_Celon_Pharma_ws_emisji_w_ramach_kapitalu_docelowego.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a formal legal act ('AKT NOTARIALNY' / Notarial Deed) dated May 10, 2021, executed before a notary public in Poland. The content details a resolution ('UCHWAŁA NR 1/2021 Zarządu') by the Management Board of CELON PHARMA Spółka Akcyjna concerning the increase of the share capital ('podwyższenia kapitału zakładowego') through the issuance of new shares ('emisję... akcji zwykłych na okaziciela serii D') via a public offering ('oferty publicznej'). This action directly relates to changes in the company's capital structure and fundraising activities. This aligns best with the 'Capital/Financing Update' category (CAP), as it is a formal legal document detailing a capital increase plan, rather than a general regulatory announcement (RNS) or a standard financial report (10-K, IR).
2021-05-11 Polish
Podjęcie uchwały w sprawie emisji akcji w ramach docelowego podwyższenia kapitału zakładowego i uchylenie poprzedniej uchwały - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text, written in Polish, discusses the Management Board's resolution ('uchwałę') regarding the issuance of new ordinary shares ('emisji... akcji') as part of a targeted increase in share capital ('podwyższenia kapitału zakładowego'). It explicitly mentions the decision to issue shares and the revocation of a previous resolution concerning the same capital increase. This action directly relates to changes in the company's capital structure and the issuance of new stock. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is short (1210 chars) but it is announcing a specific corporate action (issuing shares) rather than just announcing that a report is attached, making SHA more appropriate than RPA or RNS.
2021-05-11 Polish
Dokonanie wpisu w KRS kapitału docelowego oraz warunkowego podwyższenia kapitału zakładowego Spółki - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text, written in Polish, announces official registration entries made by the National Court Register (KRS) regarding changes to the company's charter (Statut). Specifically, it details the registration of the authorized capital (kapitału docelowego) and a conditional increase in share capital (warunkowego podwyższenia kapitału zakładowego) related to incentive programs (warrantów subskrypcyjnych). These actions directly relate to changes in the company's capital structure and share issuance mechanisms. This aligns best with the 'Share Issue/Capital Change' category (SHA), which covers capital structure changes and new share issues, even if the immediate trigger is a court registration of prior shareholder resolutions.
2021-05-06 Polish
Statut po zmianach zarejestrowanych
Governance Information Classification · 1% confidence The document text is titled "Statut Spółki 'CELON PHARMA' Spółka Akcyjna" (Statute of the Company 'CELON PHARMA' Joint Stock Company). It details the company's general provisions, subject of activity (PKD codes), share capital structure (including different series of shares, nominal value, and authorized capital increases), and provisions related to shareholder voting rights and management authorization. This content is characteristic of a company's foundational governing document, which is typically filed as part of corporate governance or charter documentation. Among the provided codes, 'Governance Information' (CGR) is the most appropriate fit for a company statute or charter, as it defines the internal rules and structure.
2021-04-13 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.